KBC Group
ARQT icon

KBC Group’s Arcutis Biotherapeutics ARQT Stock Holding History

KBC Group’s Portfolio ARQT Stock Details ARQT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$115K Hold
4,376
– – ﹤0.01% 1329
2026
Q1 		$103K Buy
4,376
+1,321
+43% +$33.7K ﹤0.01% 1300
2025
Q4 		$89K Hold
3,055
– – ﹤0.01% 1358
2025
Q3 		$58K Hold
3,055
– – ﹤0.01% 1591
2025
Q2 		$43K Sell
3,055
-2,313
-43% -$32.4K ﹤0.01% 1654
2025
Q1 		$84K Buy
+5,368
New +$75.6K ﹤0.01% 1582

Other funds holding ARQT

SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

KBC Group's ARQT Position: Q2 2026 in Review

KBC Group held its Arcutis Biotherapeutics (ARQT) position steady in Q2 2026 at 4,376 shares worth $115K. The position accounts for ﹤0.01% of the portfolio, ranked #1329.

KBC Group first reported a position in ARQT in Q1 2025 and has held it in 6 quarters since. 272 funds tracked by Wall St. Rank hold ARQT as of Q2 2026.

  • KBC Group held 4,376 shares of Arcutis Biotherapeutics worth $115K as of Q2 2026.
  • KBC Group left its Arcutis Biotherapeutics share count unchanged in Q2 2026.
  • Arcutis Biotherapeutics made up ﹤0.01% of KBC Group's portfolio in Q2 2026, its #1329 holding.
  • KBC Group first reported a position in Arcutis Biotherapeutics in Q1 2025 and has held it in 6 quarters since.
  • 272 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q2 2026.

Based on KBC Group's 13F filing for Q2 2026, filed 5 Aug 2026.